Related Experiment Video
Updated: Nov 30, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
CRIPTO antagonist ALK4L75A-Fc inhibits breast cancer cell plasticity and adaptation to stress
Ozlen Balcioglu1, Richard E Heinz1, David W Freeman1,2
1Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
Background:
CRIPTO is a multi-functional signaling protein that promotes stemness and oncogenesis. We previously developed a CRIPTO antagonist, ALK4L75A-Fc, and showed that it causes loss of the stem cell phenotype in normal mammary epithelia suggesting it may similarly inhibit CRIPTO-dependent plasticity in breast cancer cells.
Methods:
We focused on two triple negative breast cancer cell lines (MDA-MB-231 and MDA-MB-468) to measure the effects of ALK4L75A-Fc on cancer cell behavior under nutrient deprivation and endoplasmic reticulum stress. We characterized the proliferation and migration of these cells in vitro using time-lapse microscopy and characterized stress-dependent changes in the levels and distribution of CRIPTO signaling mediators and cancer stem cell markers. We also assessed the effects of ALK4L75A-Fc on proliferation, EMT, and stem cell markers in vivo as well as on tumor growth and metastasis using inducible lentiviral delivery or systemic administration of purified ALK4L75A-Fc, which represents a candidate therapeutic approach.
Results:
ALK4L75A-Fc inhibited adaptive responses of breast cancer cells under conditions of nutrient and ER stress and reduced their proliferation, migration, clonogenicity, and expression of EMT and cancer stem cell markers. ALK4L75A-Fc also inhibited proliferation of human breast cancer cells in stressed tumor microenvironments in xenografts and reduced both primary tumor size and metastatic burden.
Conclusions:
Cancer cell adaptation to stresses such as nutrient deprivation, hypoxia, and chemotherapy can critically contribute to dormancy, metastasis, therapy resistance, and recurrence. Identifying mechanisms that govern cellular adaptation, plasticity, and the emergence of stem-like cancer cells may be key to effective anticancer therapies. Results presented here indicate that targeting CRIPTO with ALK4L75A-Fc may have potential as such a therapy since it inhibits breast cancer cell adaptation to microenvironmental challenges and associated stem-like and EMT phenotypes.
Insights
This study shows that targeting CRIPTO (a protein promoting cancer stemness) with ALK4L75A-Fc inhibits breast cancer cell adaptation to stress. This suggests ALK4L75A-Fc may be a potential therapy for reducing tumor growth and metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- CRIPTO is a key protein driving cancer stemness and oncogenesis.
- A CRIPTO antagonist, ALK4L75A-Fc, was previously developed.
- This antagonist may inhibit CRIPTO-dependent plasticity in breast cancer cells.
Purpose of the Study:
- To investigate the effects of ALK4L75A-Fc on triple-negative breast cancer cells under nutrient deprivation and ER stress.
- To evaluate the therapeutic potential of ALK4L75A-Fc in inhibiting cancer cell adaptation, proliferation, migration, and metastasis.
Main Methods:
- Utilized two triple-negative breast cancer cell lines (MDA-MB-231, MDA-MB-468).
- Assessed cell proliferation and migration in vitro using time-lapse microscopy.
- Evaluated effects in vivo on tumor growth and metastasis in xenografts.
Main Results:
- ALK4L75A-Fc inhibited adaptive responses to nutrient and ER stress.
- Reduced proliferation, migration, clonogenicity, and expression of EMT and cancer stem cell markers.
- Inhibited tumor growth and reduced metastasis in vivo.
Conclusions:
- Targeting CRIPTO with ALK4L75A-Fc inhibits breast cancer cell adaptation to microenvironmental challenges.
- This approach shows potential for treating breast cancer by targeting stem-like and EMT phenotypes.
- ALK4L75A-Fc represents a candidate therapeutic strategy for breast cancer.
More Related Videos
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Abnormal Proliferation
Drugs that Destabilize Microtubules

